EP4685160A3 — Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
Assigned to Amgen Inc · Expires 2026-04-08 · 0y expired
What this patent protects
The present invention provides combination therapy that includes an KRAS<sup>G12C</sup> inhibitor, such asor a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention…
USPTO Abstract
The present invention provides combination therapy that includes an KRAS<sup>G12C</sup> inhibitor, such asor a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRAS<sup>G12C</sup> inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.